N-(Boc-L-phenylalanyl)furfurylamine | 173899-72-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(Boc-L-phenylalanyl)furfurylamine
• 英文别名: tert-butyl N-[(2S)-1-(furan-2-ylmethylamino)-1-oxo-3-phenylpropan-2-yl]carbamate
• CAS: 173899-72-4
• 化学式: C₁₉H₂₄N₂O₄
• 分子量: 344.411
• InChiKey: YQGGITWHLXAOFU-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(Boc-L-phenylalanyl)furfurylamine 在 盐酸 、 4-二甲氨基吡啶 、 1-羟基苯并三唑 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors

  摘要：

  Aminopeptidase N (APN/CD13) is one of the essential proteins for tumour invasion, angiogenesis and metastasis as it is over-expressed on the surface of different tumour cells. Based on our previous work that L-isoserine dipeptide derivatives were potent APN inhibitors, we designed and synthesized L-isoserine tripeptide derivatives as APN inhibitors. Among these compounds, one compound 16l (IC50 = 2.51 +/- 0.2 +/- mu M) showed similar inhibitory effect compared with control compound Bestatin (IC50 = 6.25 +/- 0.4 mu M) and it could be used as novel lead compound for the APN inhibitors development as anticancer agents in the future.

  DOI：

  10.3109/14756366.2012.680062
• 作为产物：
  描述：

  L-苯丙氨酸 在 4-二甲氨基吡啶 、 1-羟基苯并三唑 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 14.25h， 生成 N-(Boc-L-phenylalanyl)furfurylamine
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors

  摘要：

  Aminopeptidase N (APN/CD13) is one of the essential proteins for tumour invasion, angiogenesis and metastasis as it is over-expressed on the surface of different tumour cells. Based on our previous work that L-isoserine dipeptide derivatives were potent APN inhibitors, we designed and synthesized L-isoserine tripeptide derivatives as APN inhibitors. Among these compounds, one compound 16l (IC50 = 2.51 +/- 0.2 +/- mu M) showed similar inhibitory effect compared with control compound Bestatin (IC50 = 6.25 +/- 0.4 mu M) and it could be used as novel lead compound for the APN inhibitors development as anticancer agents in the future.

  DOI：

  10.3109/14756366.2012.680062

文献信息

• Aziridine derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05668128A1

  公开（公告）日：1997-09-16

  The present invention relates to a compound of the formula: ##STR1## wherein R.sub.1 and Q are independently an optionally esterified or amidated carboxyl group; R.sub.2 is hydrogen, an acyl group or an optionally substituted hydrocarbon residue; X is a divalent hydrocarbon residue which may be substituted; or a salt thereof, which is useful as prophylactic and therapeutic agents of bone diseases and as agents for inhibiting thiol protease.

  本发明涉及一种化合物，其化学式为：##STR1## 其中R.sub.1和Q分别是可选择酯化或酰胺化的羧基；R.sub.2是氢、酰基或可选择取代的碳氢残基；X是可能被取代的二价碳氢残基；或其盐，可用作预防和治疗骨疾病的药剂以及抑制硫醇蛋白酶的药剂。
• AZIRIDINE DERIVATIVES, THEIR PRODUCTION AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0753003B1

  公开（公告）日：1999-06-16
• US5668128A
  申请人：——

  公开号：US5668128A

  公开（公告）日：1997-09-16